Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
Search Icon
Search Icon
Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Latest Research

Filter Applied. Clear All

Latest Posts

June 10, 2026 EXCLUSIVE: Many Women Blindsided By Abortion Pill Complications, New Study Shows EXCLUSIVE: Many Women Blindsided By Abortion Pill Complications, New Study Shows June 10, 2026 New Study Finds Informed Consent Gaps for Abortion Drugs as Women Report Unexpected Pain, Bleeding New Study Finds Informed Consent Gaps for Abortion Drugs as Women Report Unexpected Pain, Bleeding June 9, 2026 Substance Use Disorder in Pregnant Women: State of the Problem, Treatment, and Recommendations for Improving Interventions Substance Use Disorder in Pregnant Women: State of the Problem, Treatment, and Recommendations for Improving Interventions
Reset All Filters
Life & the Law

Dobbs Case: What Science Reveals About 15-Week-Old Unborn Babies

Science reveals that an unborn baby’s heart has already beat nearly 16 million times by the 15th week of gestation, or the point at which a contested Mississippi law limits elective abortion. As the Supreme Court prepares to hear oral arguments Wednesday…

Maternal & Public Health

Public Health Threat: Chemical Abortion Leads to Significantly Higher Rate of ER Visits

As the Food and Drug Administration (FDA) works toward a December 16 decision on chemical abortion safeguards, a groundbreaking new study from Charlotte Lozier Institute (CLI) shows that increased access to abortion pills creates a significant public health risk.

Fetal Tissue, Stem Cells & Bioethics

Closing the Slippery Slope from a 14-Day Rule to an N-Day Rule

The 14-day limit is related to the approximate time in normal human embryonic development when structures appear in developing human beings that are the earliest stages of the formation of the nervous system.  This ethics agreement is the warned slippery slope of…

A Longitudinal Cohort Study of Emergency Room Utilization Following Mifepristone Chemical and Surgical Abortions, 1999–2015
Maternal & Public Health

A Longitudinal Cohort Study of Emergency Room Utilization Following Mifepristone Chemical and Surgical Abortions, 1999–2015

Existing research on postabortion emergency room visits is sparse and limited by methods which underestimate the incidence of adverse events following abortion. Postabortion emergency room (ER) use since Food and Drug Administration approval of chemical abortion in 2000 can identify trends in…

Maternal & Public Health

Abortion Reporting: North Dakota (2020)

In 2020, there were 1,171 abortions reported in North Dakota, up four percent from the previous year. Chemical abortions reached a record high, surging by 106 percent from 360 in 2019 to 743 in 2020.

Maternal & Public Health

Abortion Reporting: Connecticut (2019)

There were 9,202 abortions reported in Connecticut in 2019, down nearly one percent from the previous year. However, chemical abortions jumped 14 percent between 2018 and 2019, making up 50 percent of the total in 2019.

Deaths and Severe Adverse Events after the use of Mifepristone as an Abortifacient from September 2000 to February 2019
Maternal & Public Health

Deaths and Severe Adverse Events after the use of Mifepristone as an Abortifacient from September 2000 to February 2019

Objectives: Primary: Analyze the Adverse Events (AEs) reported to the Food and Drug Administration (FDA) after use of mifepristone as an abortifacient. Secondary: Analyze maternal intent after ongoing pregnancy and investigate hemorrhage after mifepristone alone.

Maternal & Public Health

Midtrimester Abortion Epidemiology, Indications and Mortality

This paper will address epidemiology, complications, indications, procedures and protocols, and women’s reasons for undergoing second trimester induced abortion.

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image